Moreover, the higher enrichment of resting memory CD4 + T cells in the CRG and immune high-risk subgroups implies that their activation, proliferation, and differentiation into specific Th subsets may offer new insights into the pathogenesis and therapy for gliomas [37]. The gene discussed is CD4; the disease is central nervous system cancer.